GLP-1 receptor agonists may offer therapeutic value ... Please see the original reference for a full list of authors’ disclosures.

The acronym GLP-1 has become an increasingly popular term in the health arena, especially in the context of weight loss.

Shares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...

which are both based on the GLP-1 receptor agonist. Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts by Novo Nordisk to ramp up its production capacity for semaglutide.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Medicaid plans often put up barriers around newer classes of diabetes medications that offer cardioprotection, according to a ...

Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

A new study raises mental health concerns about popular weight loss drugs like Ozempic and Mounjaro. These GLP-1 agonists, while effective for appetite control, may disrupt dopamine pathways linked to ...

had restricted GLP-1 receptor agonist availability. Unrestricted availability was defined as having at least one medication in each class listed on the preferred drug list without prior ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.